Obesity drugs - especially Novo Nordic's Ozempic - dominated healthcare headlines in 2024, but Matt Miskin of John Hancock ...

Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other ...

A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Pharma stocks have underperformed the market in the fourth quarter with the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--down 9.4% against a ...

Allstate Corp. Dep. Pfd. (Rep. 1/1000th Perp. Pfd. Series H) ALL.PRH 2.29% JPMorgan Chase & Co. Dep. Pfd. (Rep. 1/400th Pfd. Series EE) JPM.PRC 2.29% JPMorgan Chase ...

© 2025 The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

Tata Motors, IndusInd Bank, and Axis Bank are the stocks that hit a 52-week low in both Sensex and Nifty.

We read every day so you don't have to. Sign up for CNN Business' nightly newsletter for the top stories you need to know.